14Apr 2025
Updated ECIL Guidelines Refine Antifungal Prophylaxis in HM

Updated ECIL Guidelines Refine Antifungal Prophylaxis in HM

The 10th ECIL meeting updated prophylaxis strategies for invasive fungal diseases. Isavuconazole, micafungin, and caspofungin received B-II grades for AML/MDS patients. Posaconazole is now supported for high-risk MDS on azacytidine. CAR-T recipients are addressed for the first time, with mold-active prophylaxis recommended in high-risk patients. Pediatric guidelines now include caspofungin (B-I) and expanded prophylaxis for older ALL patients.

  • #oncology

Like

Save

Share